Buy Urispas

Urispas

Urispas: Flavoxate Pill Overview

Product name: Urispas Active ingredient: Flavoxate 200 mg per pill Therapeutic class: Urological health - antispasmodic agent Formulation: Oral tablet (pill)

Urispas is a prescription medication marketed in Hong Kong that contains the antispasmodic agent flavoxate. It is used to relieve symptoms associated with urinary bladder spasms, such as urgency, frequency, and discomfort. The drug is regulated by the Hong Kong Department of Health and is only available with a medical prescription.

How Flavoxate Works in the Body

Flavoxate belongs to the antispasmodic (smooth-muscle relaxant) group. It exerts its effect by stabilising the bladder wall and reducing involuntary detrusor muscle contractions. The exact biochemical pathway is not fully defined, but flavoxate is thought to act on cellular calcium influx, thereby decreasing the excitability of smooth-muscle cells.

Key pharmacologic points:

• Onset of action: Clinical relief typically begins within 30-60 minutes after oral ingestion.
• Peak effect: Reached about 2-3 hours post-dose.
• Duration: Effects last approximately 4-6 hours, which is why dosing is usually divided throughout the day.
• Metabolism: Flavoxate is rapidly absorbed from the gastrointestinal tract, extensively metabolised in the liver, and eliminated primarily via the kidneys.

By reducing the frequency and intensity of bladder spasms, flavoxate helps alleviate urgency, frequency, and the painful sensation of a “spasm-filled” bladder.

Conditions Treated with Urispas

In Hong Kong, flavoxate (Urispas) is approved for the symptomatic relief of bladder irritability associated with:

• Urinary frequency and urgency not caused by infection.
• Spasmodic cystitis (inflammation that leads to involuntary bladder contractions).
• Painful bladder syndrome when other causes have been excluded.

It is not indicated for the treatment of urinary tract infections, kidney stones, or prostate enlargement, although it may be used adjunctively when those conditions coexist and cause bladder spasms.

Off-Label and Investigational Applications

Current peer-reviewed literature does not provide strong evidence for off-label uses of flavoxate in other urological or non-urological conditions. Consequently, this article does not list any off-label applications. If a healthcare professional considers flavoxate for an unapproved indication, the use must be under strict medical supervision and documented informed consent.

Who Should (and Should Not) Use Urispas?

Ideal patient profile

• Adults experiencing bladder-spasm symptoms without active infection.
• Individuals whose symptoms persist despite behavioral measures (fluid management, timed voiding).

Absolute contraindications

• Known hypersensitivity to flavoxate or any excipients in the tablet.
• Severe urinary retention or uncontrolled narrow-angle glaucoma (anticholinergic-like effects may exacerbate these conditions).

Relative contraindications

• Moderate renal impairment (dose adjustment may be required).
• Hepatic dysfunction (use with caution, monitor liver enzymes).
• Pregnancy (category B in many jurisdictions; safety data limited).
• Lactation (flavoxate is excreted in breast milk; assess risk-benefit).

Special populations

• Elderly: May be more sensitive to anticholinergic side effects; start at the lowest effective dose.
• Patients with gastrointestinal disorders: Absorption may be altered; monitor therapeutic response.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Dry mouth - frequently reported, usually mild.
• Mild constipation - can be managed with dietary fibre and fluids.
• Dizziness or light-headedness - often transient after the first dose.
• Headache - typically resolves within a few days.

Serious Adverse Events

• Acute urinary retention - rare but requires immediate medical attention.
• Severe allergic reaction (rash, swelling, breathing difficulty) - seek emergency care.

Drug Interactions

• Anticholinergic agents (e.g., oxybutynin, amitriptyline) - may amplify bladder-relaxing effects and increase risk of retention.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) - could raise flavoxate plasma levels; monitor for enhanced side effects.
• Diuretics - concurrent use may alter fluid balance; advise patients to report any sudden changes in urine output.

Note: Comprehensive interaction data for flavoxate is limited. Patients should disclose all medicines, supplements, and herbal products to their healthcare provider before starting Urispas.

Food and Lifestyle Interactions

• Food: Flavoxate can be taken with or without food; taking it with meals may reduce gastrointestinal discomfort.
• Alcohol: Moderate consumption is unlikely to cause problems, but excess alcohol can increase dizziness.
• Driving: Caution is advised until the individual knows how flavoxate affects them, especially if they experience dizziness.

How to Take Urispas

• Standard dosing: The usual adult dose is one 200 mg tablet taken orally three times daily (after breakfast, lunch, and dinner).
• Special dosing considerations:
• Renal impairment: For patients with a creatinine clearance <30 mL/min, the dose may be reduced to one tablet twice daily.
• Hepatic impairment: Start with one tablet twice daily; adjust based on clinical response.
• Administration tips: Swallow the tablet whole with a full glass of water. Do not crush or chew unless instructed by a pharmacist.
• Missed dose: Take the missed tablet as soon as remembered, unless it is close to the time of the next scheduled dose. Do not double the dose.
• Overdose: Symptoms may include severe dizziness, nausea, vomiting, and profound urinary retention. Seek urgent medical care; treatment is symptomatic.
• Discontinuation: Flavoxate does not typically require tapering. However, abrupt cessation may lead to a return of bladder-spasm symptoms; discuss any changes with a clinician.

Monitoring and Follow-Up

• Clinical assessment: Re-evaluate symptom control after 2-4 weeks of therapy.
• Renal function: Check serum creatinine and estimated glomerular filtration rate (eGFR) at baseline and periodically in patients with known kidney disease.
• Liver enzymes: Monitor ALT/AST if underlying hepatic disease is present.
• Adverse events: Promptly report any signs of urinary retention, severe dizziness, or allergic reactions.

Storage and Handling

• Store tablets at room temperature (15-30 °C) away from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiration date printed on the package.
• Dispose of unused tablets according to local pharmacy take-back programs or Hong Kong Department of Health guidelines for pharmaceutical waste.

Medication-Specific Glossary

Antispasmodic

A drug that reduces involuntary smooth-muscle contractions, relieving spasm-related symptoms.

Detrusor muscle

The smooth-muscle layer of the bladder wall responsible for contraction during urination.

Urinary urgency

A sudden, compelling need to urinate that is difficult to defer.

Bladder irritability

A condition where the bladder wall reacts excessively to normal filling, causing frequency and urgency.

Pharmacokinetics

The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.

Medical Disclaimer

This article provides educational information about Urispas and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.